{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T20:59:33Z","timestamp":1794344373086,"version":"4.9.0"},"reference-count":94,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,13]],"date-time":"2023-05-13T00:00:00Z","timestamp":1683936000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,13]],"date-time":"2023-05-13T00:00:00Z","timestamp":1683936000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Deficiency of adenosine deaminase 2 (DADA2) is a rare monogenic autoinflammatory disease, whose clinical phenotype was expanded since the first cases, originally described as mimicker of polyarteritis nodosa, with immunodeficiency and early-onset stroke.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic review according to PRISMA approach, including all articles published before the 31st of August 2021 in Pubmed and EMBASE database was performed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The search identified 90 publications describing 378 unique patients (55.8% male). To date 95unique mutations have been reported. The mean age at disease onset was 92.15\u00a0months (range 0\u2013720\u00a0months), 32 (8.5%) showed an onset of the first signs\/symptoms after 18\u00a0years old and 96 (25.4%) after 10\u00a0years old. The most frequent clinical characteristics described were cutaneous (67.9%), haematological manifestations (56.3%), recurrent fever (51.3%), neurological as stroke and polyneuropathy (51%), immunological abnormalities (42.3%), arthralgia\/arthritis (35.4%), splenomegaly (30.6%), abdominal involvement (29.8%), hepatomegaly (23.5%), recurrent infections (18.5%), myalgia (17.9%), kidney involvement (17.7%) etc. Patients with skin manifestations were older than the others (101.1\u00a0months SD\u2009\u00b1\u2009116.5, vs. 75.3 SD\u2009\u00b1\u200988.2, p 0.041), while those with a haematological involvement (64.1\u00a0months SD\u2009\u00b1\u200975.6 vs. 133.1 SD\u2009\u00b1\u2009133.1, p\u2009&lt;\u20090.001) and immunological involvement (73.03\u00a0months SD\u2009\u00b1\u200996.9 vs. 103.2 SD\u2009\u00b1\u2009112.9, p 0.05) are younger than the others. We observed different correlations among the different clinical manifestations. The use of anti-TNF\u03b1 and hematopoietic cell stems transplantation (HCST) has improved the current history of the disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Due to this highly variable phenotype and age of presentation, patients with DADA2 may present to several type of specialists. Given the important morbidity and mortality, early diagnosis and treatment are mandatory.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-023-02721-6","type":"journal-article","created":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T09:11:45Z","timestamp":1684141905000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["A wide spectrum of phenotype of deficiency of deaminase 2 (DADA2): a systematic literature review"],"prefix":"10.1186","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6418-3254","authenticated-orcid":false,"given":"Ilaria","family":"Maccora","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerio","family":"Maniscalco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Campani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Carrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Abbati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo","family":"Marrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Vincenza","family":"Mastrolia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Simonini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,13]]},"reference":[{"issue":"10","key":"2721_CR1","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1056\/NEJMoa1307361","volume":"370","author":"Q Zhou","year":"2014","unstructured":"Zhou Q, Yang D, Ombrello AK, et al. Early-onset stroke and vasculopathy associated with mutations in ADA2. N Engl J Med. 2014;370(10):911\u201320. https:\/\/doi.org\/10.1056\/NEJMoa1307361.","journal-title":"N Engl J Med"},{"issue":"10","key":"2721_CR2","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1056\/NEJMoa1307362","volume":"370","author":"P Navon Elkan","year":"2014","unstructured":"Navon Elkan P, Pierce SB, Segel R, et al. Mutant adenosine deaminase 2 in a polyarteritis nodosa vasculopathy. N Engl J Med. 2014;370(10):921\u201331. https:\/\/doi.org\/10.1056\/NEJMoa1307362.","journal-title":"N Engl J Med"},{"key":"2721_CR3","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.jpeds.2016.06.058","volume":"177","author":"T Ben-Ami","year":"2016","unstructured":"Ben-Ami T, Revel-Vilk S, Brooks R, et al. Extending the clinical phenotype of adenosine deaminase 2 deficiency. J Pediatr. 2016;177:316\u201320. https:\/\/doi.org\/10.1016\/j.jpeds.2016.06.058.","journal-title":"J Pediatr"},{"issue":"1","key":"2721_CR4","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.jaci.2014.10.010","volume":"135","author":"L van Eyck","year":"2015","unstructured":"van Eyck L, Hershfield MS, Pombal D, et al. Hematopoietic stem cell transplantation rescues the immunologic phenotype and prevents vasculopathy in patients with adenosine deaminase 2 deficiency. J Allergy Clin Immunol. 2015;135(1):283-7.e5. https:\/\/doi.org\/10.1016\/j.jaci.2014.10.010.","journal-title":"J Allergy Clin Immunol"},{"key":"2721_CR5","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.3389\/fimmu.2018.01361","volume":"9","author":"JM Springer","year":"2018","unstructured":"Springer JM, Gierer SA, Jiang H, et al. Deficiency of adenosine deaminase 2 in adult siblings: many years of a misdiagnosed disease with severe consequences. Front Immunol. 2018;9:1361. https:\/\/doi.org\/10.3389\/fimmu.2018.01361.","journal-title":"Front Immunol"},{"issue":"16","key":"2721_CR6","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1056\/NEJMc1801927","volume":"380","author":"AK Ombrello","year":"2019","unstructured":"Ombrello AK, Qin J, Hoffmann PM, et al. Treatment strategies for deficiency of adenosine deaminase 2. N Engl J Med. 2019;380(16):1582\u20134. https:\/\/doi.org\/10.1056\/NEJMc1801927.","journal-title":"N Engl J Med"},{"issue":"3","key":"2721_CR7","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s10875-016-0245-x","volume":"36","author":"J Schepp","year":"2016","unstructured":"Schepp J, Bulashevska A, Mannhardt-Laakmann W, et al. Deficiency of adenosine deaminase 2 causes antibody deficiency. J Clin Immunol. 2016;36(3):179\u201386. https:\/\/doi.org\/10.1007\/s10875-016-0245-x.","journal-title":"J Clin Immunol"},{"issue":"6","key":"2721_CR8","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1016\/j.jaci.2019.12.908","volume":"145","author":"PY Lee","year":"2020","unstructured":"Lee PY, Kellner ES, Huang Y, et al. Genotype and functional correlates of disease phenotype in deficiency of adenosine deaminase 2 (DADA2). J Allergy Clin Immunol. 2020;145(6):1664-1672.e10. https:\/\/doi.org\/10.1016\/j.jaci.2019.12.908.","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"2721_CR9","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1093\/rheumatology\/kev439","volume":"55","author":"JM van Montfrans","year":"2016","unstructured":"van Montfrans JM, Hartman EAR, Braun KPJ, et al. Phenotypic variability in patients with ADA2 deficiency due to identical homozygous R169Q mutations. Rheumatology (Oxford). 2016;55(5):902\u201310. https:\/\/doi.org\/10.1093\/rheumatology\/kev439.","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"2721_CR10","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1056\/NEJMc1405506","volume":"371","author":"L van Eyck","year":"2014","unstructured":"van Eyck L, Liston A, Meyts I. Mutant ADA2 in vasculopathies. N Engl J Med. 2014;371(5):478\u201381. https:\/\/doi.org\/10.1056\/NEJMc1405506.","journal-title":"N Engl J Med"},{"issue":"9","key":"2721_CR11","doi-asserted-by":"publisher","first-page":"4373","DOI":"10.1093\/rheumatology\/keaa837","volume":"60","author":"S Cooray","year":"2021","unstructured":"Cooray S, Omyinmi E, Hong Y, et al. Anti-tumour necrosis factor treatment for the prevention of ischaemic events in patients with deficiency of adenosine deaminase 2 (DADA2). Rheumatology (Oxford). 2021;60(9):4373\u20138. https:\/\/doi.org\/10.1093\/rheumatology\/keaa837.","journal-title":"Rheumatology (Oxford)"},{"issue":"24","key":"2721_CR12","doi-asserted-by":"publisher","first-page":"2682","DOI":"10.1182\/blood-2017-07-798660","volume":"130","author":"H Hashem","year":"2017","unstructured":"Hashem H, Kumar AR, M\u00fcller I, et al. Hematopoietic stem cell transplantation rescues the hematological, immunological, and vascular phenotype in DADA2. Blood. 2017;130(24):2682\u20138. https:\/\/doi.org\/10.1182\/blood-2017-07-798660.","journal-title":"Blood"},{"issue":"11","key":"2721_CR13","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1038\/bmt.2017.173","volume":"52","author":"H Hashem","year":"2017","unstructured":"Hashem H, Vatsayan A, Gupta A, Nagle K, Hershfield M, Dalal J. Successful reduced intensity hematopoietic cell transplant in a patient with deficiency of adenosine deaminase 2. Bone Marrow Transplant. 2017;52(11):1575\u20136. https:\/\/doi.org\/10.1038\/bmt.2017.173.","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"2721_CR14","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097. https:\/\/doi.org\/10.1371\/journal.pmed.1000097.","journal-title":"PLoS Med"},{"issue":"5","key":"2721_CR15","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1056\/NEJMc1405506","volume":"371","author":"L Van Eyck","year":"2014","unstructured":"Van Eyck L, Liston A, Wouters C. Mutant ADA2 in vasculopathies. N Engl J Med. 2014;371(5):478\u201381. https:\/\/doi.org\/10.1056\/NEJMc1405506.","journal-title":"N Engl J Med"},{"issue":"3","key":"2721_CR16","doi-asserted-by":"publisher","first-page":"236","DOI":"10.4103\/injr.injr_36_19","volume":"14","author":"Z Al Mosawi","year":"2019","unstructured":"Al Mosawi Z, Abduljawad H, Busehail M, Al MB. Adenosine deaminase 2 deficiency with a novel variant of CECR1 gene mutation: responding to tumor necrosis factor antagonist therapy. Indian J Rheumatol. 2019;14(3):236. https:\/\/doi.org\/10.4103\/injr.injr_36_19.","journal-title":"Indian J Rheumatol"},{"issue":"1","key":"2721_CR17","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/s10875-019-0590-7","volume":"39","author":"F Alabbas","year":"2019","unstructured":"Alabbas F, Elyamany G, Alsharif O, Hershfield M, Meyts I. Childhood Hodgkin lymphoma: think DADA2. J Clin Immunol. 2019;39(1):26\u20139. https:\/\/doi.org\/10.1007\/s10875-019-0590-7.","journal-title":"J Clin Immunol"},{"key":"2721_CR18","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.26912","author":"A Alsultan","year":"2018","unstructured":"Alsultan A, Basher E, Alqanatish J, Mohammed R, Alfadhel M. Deficiency of ADA2 mimicking autoimmune lymphoproliferative syndrome in the absence of livedo reticularis and vasculitis. Pediatr Blood Cancer. 2018. https:\/\/doi.org\/10.1002\/pbc.26912.","journal-title":"Pediatr Blood Cancer"},{"issue":"12","key":"2721_CR19","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1002\/ajmg.a.61363","volume":"179","author":"O Akgun-Dogan","year":"2019","unstructured":"Akgun-Dogan O, Simsek-Kiper PO, Taskiran E, et al. ADA2 deficiency in a patient with Noonan syndrome-like disorder with loose anagen hair: the co-occurrence of two rare syndromes. Am J Med Genet A. 2019;179(12):2474\u201380. https:\/\/doi.org\/10.1002\/ajmg.a.61363.","journal-title":"Am J Med Genet A"},{"issue":"3","key":"2721_CR20","doi-asserted-by":"publisher","first-page":"338","DOI":"10.5606\/ArchRheumatol.2019.7075","volume":"34","author":"D Alaygut","year":"2019","unstructured":"Alaygut D, Alparslan C, \u00d6ncel EP, et al. A child diagnosed with treatment-resistant polyarteritis nodosa: can the clinical diagnosis be different? Arch Rheumatol. 2019;34(3):338\u201342. https:\/\/doi.org\/10.5606\/ArchRheumatol.2019.7075.","journal-title":"Arch Rheumatol"},{"issue":"8","key":"2721_CR21","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1007\/s10875-018-0565-0","volume":"38","author":"K Arts","year":"2018","unstructured":"Arts K, Bergerson JRE, Ombrello AK, et al. Warts and DADA2: a mere coincidence? J Clin Immunol. 2018;38(8):836\u201343. https:\/\/doi.org\/10.1007\/s10875-018-0565-0.","journal-title":"J Clin Immunol"},{"key":"2721_CR22","doi-asserted-by":"publisher","first-page":"2767","DOI":"10.3389\/fimmu.2018.02767","volume":"9","author":"F Barzaghi","year":"2018","unstructured":"Barzaghi F, Minniti F, Mauro M, et al. ALPS-like phenotype caused by ADA2 deficiency rescued by allogeneic hematopoietic stem cell transplantation. Front Immunol. 2018;9:2767. https:\/\/doi.org\/10.3389\/fimmu.2018.02767.","journal-title":"Front Immunol"},{"issue":"8","key":"2721_CR23","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.3899\/jrheum.150024","volume":"42","author":"ED Batu","year":"2015","unstructured":"Batu ED, Karadag O, Taskiran EZ, et al. A case series of adenosine deaminase 2-deficient patients emphasizing treatment and genotype-phenotype correlations. J Rheumatol. 2015;42(8):1532\u20134. https:\/\/doi.org\/10.3899\/jrheum.150024.","journal-title":"J Rheumatol"},{"issue":"1","key":"2721_CR24","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s12969-020-0417-3","volume":"18","author":"A Baytaro\u011flu","year":"2020","unstructured":"Baytaro\u011flu A, Kadayif\u00e7ilar S, A\u011fin A, et al. Choroidal vascularity index as a biomarker of systemic inflammation in childhood polyarteritis nodosa and adenosine deaminase-2 deficiency. Pediatr Rheumatol Online J. 2020;18(1):29. https:\/\/doi.org\/10.1186\/s12969-020-0417-3.","journal-title":"Pediatr Rheumatol Online J"},{"key":"2721_CR25","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/1546-0096-12-44","volume":"12","author":"A Belot","year":"2014","unstructured":"Belot A, Wassmer E, Twilt M, et al. Mutations in CECR1 associated with a neutrophil signature in peripheral blood. Pediatr Rheumatol Online J. 2014;12:44. https:\/\/doi.org\/10.1186\/1546-0096-12-44.","journal-title":"Pediatr Rheumatol Online J"},{"issue":"10277","key":"2721_CR26","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/S0140-6736(20)32660-X","volume":"397","author":"G Bourgeois","year":"2021","unstructured":"Bourgeois G, Richard M, Danset M, P\u00e9rard L, Breton A-L, Berthoux E. Deficiency of adenosine deaminase 2 diagnosed at 65\u00a0years of age. Lancet. 2021;397(10277):913. https:\/\/doi.org\/10.1016\/S0140-6736(20)32660-X.","journal-title":"Lancet"},{"issue":"3","key":"2721_CR27","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1007\/s10875-020-00940-1","volume":"41","author":"JP Brooks","year":"2021","unstructured":"Brooks JP, Rice AJ, Ji W, et al. Uncontrolled Epstein-Barr virus as an atypical presentation of deficiency in ADA2 (DADA2). J Clin Immunol. 2021;41(3):680\u20133. https:\/\/doi.org\/10.1007\/s10875-020-00940-1.","journal-title":"J Clin Immunol"},{"issue":"3","key":"2721_CR28","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.neurad.2018.05.002","volume":"46","author":"E Bulut","year":"2019","unstructured":"Bulut E, Erden A, Karadag O, Oguz KK, Ozen S. Deficiency of adenosine deaminase 2; special focus on central nervous system imaging. J Neuroradiol. 2019;46(3):193\u20138. https:\/\/doi.org\/10.1016\/j.neurad.2018.05.002.","journal-title":"J Neuroradiol"},{"issue":"3","key":"2721_CR29","doi-asserted-by":"publisher","first-page":"413","DOI":"10.24953\/turkjped.2019.03.014","volume":"61","author":"M \u00c7akan","year":"2019","unstructured":"\u00c7akan M, Aktay-Ayaz N, Karada\u011f \u015eG, et al. Atypical phenotype of an old disease or typical phenotype of a new disease: deficiency of adenosine deaminase 2. Turk J Pediatr. 2019;61(3):413\u20137. https:\/\/doi.org\/10.24953\/turkjped.2019.03.014.","journal-title":"Turk J Pediatr"},{"issue":"10","key":"2721_CR30","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1136\/annrheumdis-2016-210802","volume":"76","author":"R Caorsi","year":"2017","unstructured":"Caorsi R, Penco F, Grossi A, et al. ADA2 deficiency (DADA2) as an unrecognised cause of early onset polyarteritis nodosa and stroke: a multicentre national study. Ann Rheum Dis. 2017;76(10):1648\u201356. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210802.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"2721_CR31","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1016\/j.jaad.2020.03.110","volume":"83","author":"F Chasset","year":"2020","unstructured":"Chasset F, Fayand A, Moguelet P, et al. Clinical and pathological dermatological features of deficiency of adenosine deaminase 2: a multicenter, retrospective, observational study. J Am Acad Dermatol. 2020;83(6):1794\u20138. https:\/\/doi.org\/10.1016\/j.jaad.2020.03.110.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"2721_CR32","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s10875-018-0487-x","volume":"38","author":"FE Cipe","year":"2018","unstructured":"Cipe FE, Aydogmus C, Serwas NK, Keskindemirci G, Boztu\u011f K. Novel mutation in CECR1 leads to deficiency of ADA2 with associated neutropenia. J Clin Immunol. 2018;38(3):273\u20137. https:\/\/doi.org\/10.1007\/s10875-018-0487-x.","journal-title":"J Clin Immunol"},{"key":"2721_CR33","doi-asserted-by":"publisher","DOI":"10.1101\/mcs.a003384","author":"D Claassen","year":"2018","unstructured":"Claassen D, Boals M, Bowling KM, et al. Complexities of genetic diagnosis illustrated by an atypical case of congenital hypoplastic anemia. Cold Spring Harb Mol Case Stud. 2018. https:\/\/doi.org\/10.1101\/mcs.a003384.","journal-title":"Cold Spring Harb Mol Case Stud"},{"issue":"15","key":"2721_CR34","doi-asserted-by":"publisher","first-page":"e1801","DOI":"10.1212\/WNL.0000000000007270","volume":"92","author":"TS Da Gon\u00e7alves","year":"2019","unstructured":"Da Gon\u00e7alves TS, Alves CAPF, Da Paz JA, Lucato LT. Teaching NeuroImages: Lacunar stroke and polyarteritis nodosa: consider ADA2 deficiency (DADA2). Neurology. 2019;92(15):e1801\u20132. https:\/\/doi.org\/10.1212\/WNL.0000000000007270.","journal-title":"Neurology"},{"issue":"7","key":"2721_CR35","doi-asserted-by":"publisher","first-page":"e251","DOI":"10.1097\/RHU.0000000000001384","volume":"27","author":"MD Dimachkie","year":"2021","unstructured":"Dimachkie MD, Fraga GR, Moura NS, Springer JM. A rare case of adenosine deaminase 2 deficiency presenting with temporal arteritis. J Clin Rheumatol. 2021;27(7):e251\u20132. https:\/\/doi.org\/10.1097\/RHU.0000000000001384.","journal-title":"J Clin Rheumatol"},{"issue":"6","key":"2721_CR36","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1080\/08880018.2019.1621973","volume":"36","author":"RMK Ekinci","year":"2019","unstructured":"Ekinci RMK, Balc\u0131 S, Bisgin A, et al. A homozygote novel L451W mutation in CECR1 gene causes deficiency of adenosine deaminase 2 in a pediatric patient representing with chronic lymphoproliferation and cytopenia. Pediatr Hematol Oncol. 2019;36(6):376\u201381. https:\/\/doi.org\/10.1080\/08880018.2019.1621973.","journal-title":"Pediatr Hematol Oncol"},{"issue":"2","key":"2721_CR37","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1055\/s-0036-1597611","volume":"48","author":"M Elbracht","year":"2017","unstructured":"Elbracht M, Mull M, Wagner N, et al. Stroke as initial manifestation of adenosine deaminase 2 deficiency. Neuropediatrics. 2017;48(2):111\u20134. https:\/\/doi.org\/10.1055\/s-0036-1597611.","journal-title":"Neuropediatrics"},{"issue":"4","key":"2721_CR38","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1016\/j.jaci.2015.07.053","volume":"137","author":"F Fellmann","year":"2016","unstructured":"Fellmann F, Angelini F, Wassenberg J, et al. IL-17 receptor A and adenosine deaminase 2 deficiency in siblings with recurrent infections and chronic inflammation. J Allergy Clin Immunol. 2016;137(4):1189-1196.e2. https:\/\/doi.org\/10.1016\/j.jaci.2015.07.053.","journal-title":"J Allergy Clin Immunol"},{"issue":"7","key":"2721_CR39","doi-asserted-by":"publisher","first-page":"e237","DOI":"10.1093\/rheumatology\/keab011","volume":"60","author":"MPL Ferriani","year":"2021","unstructured":"Ferriani MPL, Valera ET, de Sousa GR, et al. ADA2 deficiency (DADA2) associated with Evans syndrome and a severe ADA2 genotype. Rheumatology (Oxford). 2021;60(7):e237\u20139. https:\/\/doi.org\/10.1093\/rheumatology\/keab011.","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"2721_CR40","doi-asserted-by":"publisher","first-page":"3853","DOI":"10.1007\/s10067-020-05210-4","volume":"39","author":"S Ganh\u00e3o","year":"2020","unstructured":"Ganh\u00e3o S, Loureiro GB, Oliveira DR, et al. Two cases of ADA2 deficiency presenting as childhood polyarteritis nodosa: novel ADA2 variant, atypical CNS manifestations, and literature review. Clin Rheumatol. 2020;39(12):3853\u201360. https:\/\/doi.org\/10.1007\/s10067-020-05210-4.","journal-title":"Clin Rheumatol"},{"issue":"6","key":"2721_CR41","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1007\/s00431-014-2320-8","volume":"173","author":"N Garg","year":"2014","unstructured":"Garg N, Kasapcopur O, Foster J, et al. Novel adenosine deaminase 2 mutations in a child with a fatal vasculopathy. Eur J Pediatr. 2014;173(6):827\u201330. https:\/\/doi.org\/10.1007\/s00431-014-2320-8.","journal-title":"Eur J Pediatr"},{"issue":"3","key":"2721_CR42","doi-asserted-by":"publisher","first-page":"e60","DOI":"10.1111\/bjh.15896","volume":"186","author":"RR Ghurye","year":"2019","unstructured":"Ghurye RR, Sundaram K, Smith F, et al. Novel ADA2 mutation presenting with neutropenia, lymphopenia and bone marrow failure in patients with deficiency in adenosine deaminase 2 (DADA2). Br J Haematol. 2019;186(3):e60\u20134. https:\/\/doi.org\/10.1111\/bjh.15896.","journal-title":"Br J Haematol"},{"issue":"10","key":"2721_CR43","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1002\/art.40913","volume":"71","author":"KM Gibson","year":"2019","unstructured":"Gibson KM, Morishita KA, Dancey P, et al. Identification of novel adenosine deaminase 2 gene variants and varied clinical phenotype in pediatric vasculitis. Arthritis Rheumatol. 2019;71(10):1747\u201355. https:\/\/doi.org\/10.1002\/art.40913.","journal-title":"Arthritis Rheumatol"},{"issue":"11","key":"2721_CR44","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1001\/jamadermatol.2015.1635","volume":"151","author":"TM Gonzalez Santiago","year":"2015","unstructured":"Gonzalez Santiago TM, Zavialov A, Saarela J, et al. Dermatologic features of ADA2 deficiency in cutaneous polyarteritis nodosa. JAMA Dermatol. 2015;151(11):1230\u20134. https:\/\/doi.org\/10.1001\/jamadermatol.2015.1635.","journal-title":"JAMA Dermatol"},{"issue":"1","key":"2721_CR45","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s10875-019-00700-w","volume":"40","author":"L G\u00f6schl","year":"2020","unstructured":"G\u00f6schl L, Winkler S, Dmytrus J, et al. Unreported missense mutation in the dimerization domain of ADA2 leads to ADA2 deficiency associated with severe oral ulcers and neutropenia in a female Somalian patient-addendum to the genotype-phenotype puzzle. J Clin Immunol. 2020;40(1):223\u20136. https:\/\/doi.org\/10.1007\/s10875-019-00700-w.","journal-title":"J Clin Immunol"},{"issue":"6","key":"2721_CR46","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1111\/cge.13518","volume":"95","author":"A Grossi","year":"2019","unstructured":"Grossi A, Cusano R, Rusmini M, et al. ADA2 deficiency due to a novel structural variation in 22q11.1. Clin Genet. 2019;95(6):732\u20133. https:\/\/doi.org\/10.1111\/cge.13518.","journal-title":"Clin Genet"},{"key":"2721_CR47","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.gene.2018.01.060","volume":"649","author":"R G\u00fcnthner","year":"2018","unstructured":"G\u00fcnthner R, Wagner M, Thurm T, Ponsel S, H\u00f6fele J, Lange-Sperandio B. Identification of co-occurrence in a patient with Dent\u2019s disease and ADA2-deficiency by exome sequencing. Gene. 2018;649:23\u20136. https:\/\/doi.org\/10.1016\/j.gene.2018.01.060.","journal-title":"Gene"},{"issue":"4","key":"2721_CR48","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1007\/s10875-021-00981-0","volume":"41","author":"L Guo","year":"2021","unstructured":"Guo L, Wang J, Yang X, et al. Novel ADA2 compound heterozygous mutations resulting in deficiency of adenosine deaminase 2 in a pair of siblings. J Clin Immunol. 2021;41(4):837\u201342. https:\/\/doi.org\/10.1007\/s10875-021-00981-0.","journal-title":"J Clin Immunol"},{"issue":"5","key":"2721_CR49","doi-asserted-by":"publisher","first-page":"e293","DOI":"10.1097\/MPH.0000000000000805","volume":"39","author":"H Hashem","year":"2017","unstructured":"Hashem H, Egler R, Dalal J. Refractory pure red cell aplasia manifesting as deficiency of adenosine deaminase 2. J Pediatr Hematol Oncol. 2017;39(5):e293\u20136. https:\/\/doi.org\/10.1097\/MPH.0000000000000805.","journal-title":"J Pediatr Hematol Oncol"},{"issue":"5","key":"2721_CR50","doi-asserted-by":"publisher","first-page":"523","DOI":"10.3899\/jrheum.180045","volume":"46","author":"A Insalaco","year":"2019","unstructured":"Insalaco A, Moneta GM, Pardeo M, et al. Variable clinical phenotypes and relation of interferon signature with disease activity in ADA2 deficiency. J Rheumatol. 2019;46(5):523\u20136. https:\/\/doi.org\/10.3899\/jrheum.180045.","journal-title":"J Rheumatol"},{"issue":"5","key":"2721_CR51","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1007\/s00296-019-04252-5","volume":"39","author":"\u0130 Karacan","year":"2019","unstructured":"Karacan \u0130, Balamir A, U\u011furlu S, et al. Diagnostic utility of a targeted next-generation sequencing gene panel in the clinical suspicion of systemic autoinflammatory diseases: a multi-center study. Rheumatol Int. 2019;39(5):911\u20139. https:\/\/doi.org\/10.1007\/s00296-019-04252-5.","journal-title":"Rheumatol Int"},{"issue":"6","key":"2721_CR52","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1093\/rheumatology\/kew050","volume":"55","author":"N Keer","year":"2016","unstructured":"Keer N, Hershfield M, Caskey T, Unizony S. Novel compound heterozygous variants in CECR1 gene associated with childhood onset polyarteritis nodosa and deficiency of ADA2. Rheumatology (Oxford). 2016;55(6):1145\u20137. https:\/\/doi.org\/10.1093\/rheumatology\/kew050.","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"2721_CR53","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1080\/03009742.2020.1772868","volume":"50","author":"D Keino","year":"2021","unstructured":"Keino D, Kondoh K, Kim Y, et al. Successful treatment with cyclosporine and anti-tumour necrosis factor agent for deficiency of adenosine deaminase-2. Scand J Rheumatol. 2021;50(3):243\u20135. https:\/\/doi.org\/10.1080\/03009742.2020.1772868.","journal-title":"Scand J Rheumatol"},{"issue":"11","key":"2721_CR54","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1007\/s13312-020-2041-1","volume":"57","author":"R Khubchandani","year":"2020","unstructured":"Khubchandani R, Aksentijevich I. Deficiency of adenosine deaminase 2 (DADA2)\u2014a new autoinflammatory disease with multisystem features. Indian Pediatr. 2020;57(11):1074\u20135.","journal-title":"Indian Pediatr"},{"issue":"1","key":"2721_CR55","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1093\/rheumatology\/kez260","volume":"59","author":"RM Kisla Ekinci","year":"2020","unstructured":"Kisla Ekinci RM, Balci S, Hershfield M, et al. Deficiency of adenosine deaminase 2: a case series revealing clinical manifestations, genotypes and treatment outcomes from Turkey. Rheumatology (Oxford). 2020;59(1):254\u20136. https:\/\/doi.org\/10.1093\/rheumatology\/kez260.","journal-title":"Rheumatology (Oxford)"},{"key":"2721_CR56","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0000000000001145","author":"S Krutzke","year":"2019","unstructured":"Krutzke S, Horneff G. Treatment of two male children suffering from deficiency of adenosine deaminase type 2 (DADA2) with TNF-Inhibitor etanercept. J Clin Rheumatol. 2019. https:\/\/doi.org\/10.1097\/RHU.0000000000001145.","journal-title":"J Clin Rheumatol"},{"key":"2721_CR57","unstructured":"Lamprecht P, Humrich JY, Diebold I, Riemekasten G. Diagnosis of deficiency of adenosine deaminase 2 with early onset polyarteritis nodosa in an adult patient with a novel compound heterozygous CECR1 mutation. Clin Exp Rheumatol. 2018;36 Suppl 111(2):177. Published March 15, 2018."},{"issue":"6","key":"2721_CR58","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1007\/s10875-020-00812-8","volume":"40","author":"T Le Voyer","year":"2020","unstructured":"Le Voyer T, Boutboul D, Ledoux-Pilon A, et al. Late-onset EBV susceptibility and refractory pure red cell aplasia revealing DADA2. J Clin Immunol. 2020;40(6):948\u201353. https:\/\/doi.org\/10.1007\/s10875-020-00812-8.","journal-title":"J Clin Immunol"},{"issue":"4","key":"2721_CR59","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s00251-018-01101-w","volume":"71","author":"L Liu","year":"2019","unstructured":"Liu L, Wang W, Wang Y, et al. A Chinese DADA2 patient: report of two novel mutations and successful HSCT. Immunogenetics. 2019;71(4):299\u2013305. https:\/\/doi.org\/10.1007\/s00251-018-01101-w.","journal-title":"Immunogenetics"},{"key":"2721_CR60","unstructured":"Maccora I, Frongia I, Azzari C, Ricci S, Cimaz R, Simonini G. A misleading case of deficiency of adenosine deaminase 2 (DADA2): the magnifying glass of the scientific knowledge drives the tailored medicine in real life. Clin Exp Rheumatol. 2018;36(6 Suppl 115):146. Published July 19, 2018."},{"issue":"2","key":"2721_CR61","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1007\/s10875-018-0480-4","volume":"38","author":"TF Michniacki","year":"2018","unstructured":"Michniacki TF, Hannibal M, Ross CW, et al. Hematologic manifestations of deficiency of adenosine deaminase 2 (DADA2) and response to tumor necrosis factor inhibition in DADA2-associated bone marrow failure. J Clin Immunol. 2018;38(2):166\u201373. https:\/\/doi.org\/10.1007\/s10875-018-0480-4.","journal-title":"J Clin Immunol"},{"issue":"2","key":"2721_CR62","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.jaci.2021.01.018","volume":"148","author":"H Nihira","year":"2021","unstructured":"Nihira H, Izawa K, Ito M, et al. Detailed analysis of Japanese patients with adenosine deaminase 2 deficiency reveals characteristic elevation of type II interferon signature and STAT1 hyperactivation. J Allergy Clin Immunol. 2021;148(2):550\u201362. https:\/\/doi.org\/10.1016\/j.jaci.2021.01.018.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"2721_CR63","doi-asserted-by":"publisher","first-page":"117","DOI":"10.3899\/jrheum.181384","volume":"47","author":"S \u00d6zen","year":"2020","unstructured":"\u00d6zen S, Batu ED, Ta\u015fk\u0131ran EZ, et al. A monogenic disease with a variety of phenotypes: deficiency of adenosine deaminase 2. J Rheumatol. 2020;47(1):117\u201325. https:\/\/doi.org\/10.3899\/jrheum.181384.","journal-title":"J Rheumatol"},{"issue":"2","key":"2721_CR64","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.jaad.2016.01.057","volume":"75","author":"DC Pichard","year":"2016","unstructured":"Pichard DC, Ombrello AK, Hoffmann P, Stone DL, Cowen EW. Early-onset stroke, polyarteritis nodosa (PAN), and livedo racemosa. J Am Acad Dermatol. 2016;75(2):449\u201353. https:\/\/doi.org\/10.1016\/j.jaad.2016.01.057.","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"2721_CR65","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1007\/s12098-021-03809-2","volume":"88","author":"P Pimpale Chavan","year":"2021","unstructured":"Pimpale Chavan P, Ramadoss D, Khan A, Lee PY, Khubchandani R. Deficiency of adenosine deaminase 2 (DADA2): one disease. Several Faces Indian J Pediatr. 2021;88(8):828\u201330. https:\/\/doi.org\/10.1007\/s12098-021-03809-2.","journal-title":"Several Faces Indian J Pediatr"},{"issue":"7","key":"2721_CR66","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1038\/s41431-018-0130-6","volume":"26","author":"M Rama","year":"2018","unstructured":"Rama M, Duflos C, Melki I, et al. A decision tree for the genetic diagnosis of deficiency of adenosine deaminase 2 (DADA2): a French reference centres experience. Eur J Hum Genet. 2018;26(7):960\u201371. https:\/\/doi.org\/10.1038\/s41431-018-0130-6.","journal-title":"Eur J Hum Genet"},{"issue":"1","key":"2721_CR67","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1080\/20469047.2018.1559495","volume":"40","author":"S Sahin","year":"2020","unstructured":"Sahin S, Adrovic A, Barut K, et al. A 9.5-year-old boy with recurrent neurological manifestations and severe hypertension, treated initially for polyarteritis nodosa, was subsequently diagnosed with adenosine deaminase type 2 deficiency (DADA2) which responded to anti-TNF-\u03b1. Paediatr Int Child Health. 2020;40(1):65\u20138. https:\/\/doi.org\/10.1080\/20469047.2018.1559495.","journal-title":"Paediatr Int Child Health"},{"key":"2721_CR68","doi-asserted-by":"publisher","first-page":"108525","DOI":"10.1016\/j.clim.2020.108525","volume":"218","author":"F Saettini","year":"2020","unstructured":"Saettini F, Fazio G, Corti P, et al. Two siblings presenting with novel ADA2 variants, lymphoproliferation, persistence of large granular lymphocytes, and T-cell perturbations. Clin Immunol. 2020;218:108525. https:\/\/doi.org\/10.1016\/j.clim.2020.108525.","journal-title":"Clin Immunol"},{"issue":"1","key":"2721_CR69","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s00296-017-3740-3","volume":"38","author":"S Sahin","year":"2018","unstructured":"Sahin S, Adrovic A, Barut K, et al. Clinical, imaging and genotypical features of three deceased and five surviving cases with ADA2 deficiency. Rheumatol Int. 2018;38(1):129\u201336. https:\/\/doi.org\/10.1007\/s00296-017-3740-3.","journal-title":"Rheumatol Int"},{"issue":"5\u20136","key":"2721_CR70","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1159\/000495794","volume":"46","author":"GC Santo","year":"2018","unstructured":"Santo GC, Baldeiras I, Guerreiro R, et al. Adenosine deaminase two and immunoglobulin M accurately differentiate adult Sneddon\u2019s syndrome of unknown cause. Cerebrovasc Dis. 2018;46(5\u20136):257\u201364. https:\/\/doi.org\/10.1159\/000495794.","journal-title":"Cerebrovasc Dis"},{"issue":"8","key":"2721_CR71","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1002\/art.40147","volume":"69","author":"J Schepp","year":"2017","unstructured":"Schepp J, Proietti M, Frede N, et al. Screening of 181 patients with antibody deficiency for deficiency of adenosine deaminase 2 sheds new light on the disease in adulthood. Arthritis Rheumatol. 2017;69(8):1689\u2013700. https:\/\/doi.org\/10.1002\/art.40147.","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"2721_CR72","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1002\/art.41549","volume":"73","author":"O Schnappauf","year":"2021","unstructured":"Schnappauf O, Sampaio Moura N, Aksentijevich I, et al. Sequence-based screening of patients with idiopathic polyarteritis nodosa, granulomatosis with polyangiitis, and microscopic polyangiitis for deleterious genetic variants in ADA2. Arthritis Rheumatol. 2021;73(3):512\u20139. https:\/\/doi.org\/10.1002\/art.41549.","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"2721_CR73","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1093\/rheumatology\/key258","volume":"58","author":"A Sharma","year":"2019","unstructured":"Sharma A, Naidu GSRSNK, Chattopadhyay A, Acharya N, Jha S, Jain S. Novel CECR1 gene mutations causing deficiency of adenosine deaminase 2, mimicking antiphospholipid syndrome. Rheumatology (Oxford). 2019;58(1):181\u20132. https:\/\/doi.org\/10.1093\/rheumatology\/key258.","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"2721_CR74","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1002\/art.41500","volume":"73","author":"A Sharma","year":"2021","unstructured":"Sharma A, Naidu G, Sharma V, et al. Deficiency of adenosine deaminase 2 in adults and children: experience from India. Arthritis Rheumatol. 2021;73(2):276\u201385. https:\/\/doi.org\/10.1002\/art.41500.","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"2721_CR75","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s12969-017-0193-x","volume":"15","author":"A Skrabl-Baumgartner","year":"2017","unstructured":"Skrabl-Baumgartner A, Plecko B, Schmidt WM, et al. Autoimmune phenotype with type I interferon signature in two brothers with ADA2 deficiency carrying a novel CECR1 mutation. Pediatr Rheumatol Online J. 2017;15(1):67. https:\/\/doi.org\/10.1186\/s12969-017-0193-x.","journal-title":"Pediatr Rheumatol Online J"},{"issue":"1","key":"2721_CR76","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s00296-019-04444-z","volume":"41","author":"B Sozeri","year":"2021","unstructured":"Sozeri B, Ercan G, Dogan OA, Y\u0131ld\u0131z J, Demir F, Do\u011fanay L. The same mutation in a family with adenosine deaminase 2 deficiency. Rheumatol Int. 2021;41(1):227\u201333. https:\/\/doi.org\/10.1007\/s00296-019-04444-z.","journal-title":"Rheumatol Int"},{"key":"2721_CR77","doi-asserted-by":"publisher","first-page":"108443","DOI":"10.1016\/j.clim.2020.108443","volume":"215","author":"E Staples","year":"2020","unstructured":"Staples E, Simeoni I, Stephens JC, et al. ADA2 deficiency complicated by EBV-driven lymphoproliferative disease. Clin Immunol. 2020;215:108443. https:\/\/doi.org\/10.1016\/j.clim.2020.108443.","journal-title":"Clin Immunol"},{"key":"2721_CR78","doi-asserted-by":"publisher","DOI":"10.1080\/08820139.2020.1853153","author":"M S\u00fcleyman","year":"2020","unstructured":"S\u00fcleyman M, Tan \u00c7, Uner A, et al. Adenosine deaminase type II Deficiency: severe chronic neutropenia, lymphoid infiltration in bone marrow, and inflammatory features. Immunol Invest. 2020. https:\/\/doi.org\/10.1080\/08820139.2020.1853153.","journal-title":"Immunol Invest"},{"issue":"2","key":"2721_CR79","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1097\/MPH.0000000000001132","volume":"41","author":"M Sundin","year":"2019","unstructured":"Sundin M, Marits P, Nierkens S, Kolios AGA, Nilsson J. \u201cImmune\u201d thrombocytopenia as key feature of a novel ADA2 deficiency variant: implication on differential diagnostics of ITP in children. J Pediatr Hematol Oncol. 2019;41(2):155\u20137. https:\/\/doi.org\/10.1097\/MPH.0000000000001132.","journal-title":"J Pediatr Hematol Oncol"},{"key":"2721_CR80","doi-asserted-by":"publisher","first-page":"630691","DOI":"10.3389\/fimmu.2021.630691","volume":"12","author":"D Suri","year":"2021","unstructured":"Suri D, Rawat A, Jindal AK, et al. Spectrum of systemic auto-inflammatory diseases in India: a multi-centric experience. Front Immunol. 2021;12:630691. https:\/\/doi.org\/10.3389\/fimmu.2021.630691.","journal-title":"Front Immunol"},{"issue":"2","key":"2721_CR81","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s10875-019-00734-0","volume":"40","author":"A Tanatar","year":"2020","unstructured":"Tanatar A, Karada\u011f \u015eG, S\u00f6zeri B, et al. ADA2 deficiency: case series of five patients with varying phenotypes. J Clin Immunol. 2020;40(2):253\u20138. https:\/\/doi.org\/10.1007\/s10875-019-00734-0.","journal-title":"J Clin Immunol"},{"issue":"3","key":"2721_CR82","doi-asserted-by":"publisher","first-page":"e66","DOI":"10.1097\/RHU.0000000000000839","volume":"26","author":"V Teixeira","year":"2020","unstructured":"Teixeira V, Oliveira-Ramos F, Costa M. Severe and refractory polyarteritis nodosa associated with CECR1 mutation and dramatic response to infliximab in adulthood. J Clin Rheumatol. 2020;26(3):e66\u20139. https:\/\/doi.org\/10.1097\/RHU.0000000000000839.","journal-title":"J Clin Rheumatol"},{"issue":"4","key":"2721_CR83","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1016\/j.jaci.2018.01.012","volume":"141","author":"L Trotta","year":"2018","unstructured":"Trotta L, Martelius T, Siitonen T, et al. ADA2 deficiency: clonal lymphoproliferation in a subset of patients. J Allergy Clin Immunol. 2018;141(4):1534-1537.e8. https:\/\/doi.org\/10.1016\/j.jaci.2018.01.012.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"2721_CR84","doi-asserted-by":"publisher","first-page":"e000236","DOI":"10.1136\/rmdopen-2015-000236","volume":"2","author":"F Uettwiller","year":"2016","unstructured":"Uettwiller F, Sarrabay G, Rodero MP, et al. ADA2 deficiency: case report of a new phenotype and novel mutation in two sisters. RMD Open. 2016;2(1):e000236. https:\/\/doi.org\/10.1136\/rmdopen-2015-000236.","journal-title":"RMD Open"},{"issue":"3","key":"2721_CR85","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/j.jaip.2019.11.039","volume":"8","author":"A van de Ven","year":"2020","unstructured":"van de Ven A, Mader I, Wolff D, et al. Structural noninfectious manifestations of the central nervous system in common variable immunodeficiency disorders. J Allergy Clin Immunol Pract. 2020;8(3):1047-1062.e6. https:\/\/doi.org\/10.1016\/j.jaip.2019.11.039.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2721_CR86","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2017-2266","author":"E van Nieuwenhove","year":"2018","unstructured":"van Nieuwenhove E, Humblet-Baron S, van Eyck L, et al. ADA2 deficiency mimicking idiopathic multicentric castleman disease. Pediatrics. 2018. https:\/\/doi.org\/10.1542\/peds.2017-2266.","journal-title":"Pediatrics"},{"key":"2721_CR87","unstructured":"van Well GTJ, Kant B, van Nistelrooij A, et al. Phenotypic variability including Beh\u00e7et\u2019s disease-like manifestations in DADA2 patients due to a homozygous c.973-2AG splice site mutation. Clin Exp Rheumatol. 2019;37 Suppl 121(6):142\u2013146. Published December 9, 2019."},{"issue":"20","key":"2721_CR88","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1212\/WNL.0000000000001581","volume":"84","author":"WF Westendorp","year":"2015","unstructured":"Westendorp WF, Nederkoorn PJ, Aksentijevich I, Hak AE, Lichtenbelt KD, Braun KPJ. Unexplained early-onset lacunar stroke and inflammatory skin lesions: consider ADA2 deficiency. Neurology. 2015;84(20):2092\u20133. https:\/\/doi.org\/10.1212\/WNL.0000000000001581.","journal-title":"Neurology"},{"key":"2721_CR89","doi-asserted-by":"publisher","first-page":"642454","DOI":"10.3389\/fmed.2021.642454","volume":"8","author":"Y Xu","year":"2021","unstructured":"Xu Y, Shan Y, Hu Y, et al. Case report: an adult patient with deficiency of adenosine deaminase 2 resembled unilateral frosted branch angiitis. Front Med (Lausanne). 2021;8:642454. https:\/\/doi.org\/10.3389\/fmed.2021.642454.","journal-title":"Front Med (Lausanne)"},{"issue":"10","key":"2721_CR90","doi-asserted-by":"publisher","first-page":"4325","DOI":"10.1007\/s10067-021-05587-w","volume":"40","author":"B Zhang","year":"2021","unstructured":"Zhang B, Sun Y, Xu N, et al. Adult-onset deficiency of adenosine deaminase 2-a case report and literature review. Clin Rheumatol. 2021;40(10):4325\u201339. https:\/\/doi.org\/10.1007\/s10067-021-05587-w.","journal-title":"Clin Rheumatol"},{"issue":"1","key":"2721_CR91","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s12969-019-0334-5","volume":"17","author":"K Clarke","year":"2019","unstructured":"Clarke K, Campbell C, Omoyinmi E, et al. Testicular ischemia in deficiency of adenosine deaminase 2 (DADA2). Pediatr Rheumatol Online J. 2019;17(1):39. https:\/\/doi.org\/10.1186\/s12969-019-0334-5.","journal-title":"Pediatr Rheumatol Online J"},{"key":"2721_CR92","doi-asserted-by":"publisher","first-page":"811473","DOI":"10.3389\/fimmu.2021.811473","volume":"12","author":"KS Barron","year":"2021","unstructured":"Barron KS, Aksentijevich I, Deuitch NT, et al. The spectrum of the deficiency of adenosine deaminase 2: an observational analysis of a 60 patient cohort. Front Immunol. 2021;12:811473. https:\/\/doi.org\/10.3389\/fimmu.2021.811473.","journal-title":"Front Immunol"},{"issue":"5","key":"2721_CR93","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1016\/j.jaci.2021.10.030","volume":"149","author":"NT Deuitch","year":"2022","unstructured":"Deuitch NT, Yang D, Lee PY, et al. TNF inhibition in vasculitis management in adenosine deaminase 2 deficiency (DADA2). J Allergy Clin Immunol. 2022;149(5):1812-1816.e6. https:\/\/doi.org\/10.1016\/j.jaci.2021.10.030.","journal-title":"J Allergy Clin Immunol"},{"issue":"16","key":"2721_CR94","doi-asserted-by":"publisher","first-page":"3174","DOI":"10.1182\/bloodadvances.2020003811","volume":"5","author":"M Zoccolillo","year":"2021","unstructured":"Zoccolillo M, Brigida I, Barzaghi F, et al. Lentiviral correction of enzymatic activity restrains macrophage inflammation in adenosine deaminase 2 deficiency. Blood Adv. 2021;5(16):3174\u201387. https:\/\/doi.org\/10.1182\/bloodadvances.2020003811.","journal-title":"Blood Adv"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-023-02721-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-023-02721-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-023-02721-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T09:14:17Z","timestamp":1684142057000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-023-02721-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,13]]},"references-count":94,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2721"],"URL":"https:\/\/doi.org\/10.1186\/s13023-023-02721-6","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,13]]},"assertion":[{"value":"3 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Because this is a systematic literature review a ethical approval is not required by Meyer Children\u2019s University hospital.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Because this is a systematic literature review the consent is not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publications"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"117"}}